These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28522682)

  • 1. Regorafenib Approved for Liver Cancer.
    Cancer Discov; 2017 Jul; 7(7):660. PubMed ID: 28522682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
    Rimassa L; Pressiani T; Personeni N; Santoro A
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib: A Review in Hepatocellular Carcinoma.
    Heo YA; Syed YY
    Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib as treatment for patients with advanced hepatocellular cancer.
    Thillai K; Srikandarajah K; Ross P
    Future Oncol; 2017 Oct; 13(25):2223-2232. PubMed ID: 28766967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib: a newly approved drug for advanced hepatocellular carcinoma.
    Kyrochristos ID; Ziogas DE; Roukos DH
    Future Oncol; 2017 Aug; 13(19):1665-1668. PubMed ID: 28613123
    [No Abstract]   [Full Text] [Related]  

  • 7. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
    Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers.
    Fondevila F; Méndez-Blanco C; Fernández-Palanca P; González-Gallego J; Mauriz JL
    Exp Mol Med; 2019 Sep; 51(9):1-15. PubMed ID: 31551425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: systemic treatment of hepatocellular carcinoma.
    Pinter M; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity.
    Yoshioka N; Kuzuya T; Ito T; Ishizu Y; Honda T; Ishikawa T; Ishigami M; Fujishiro M
    Intern Med; 2019 Oct; 58(19):2803-2808. PubMed ID: 31243207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
    da Fonseca LG; Reig M; Bruix J
    Clin Liver Dis; 2020 Nov; 24(4):719-737. PubMed ID: 33012455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment.
    Kim K; Jha R; Prins PA; Wang H; Chacha M; Hartley ML; He AR
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):945-954. PubMed ID: 28932966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Approvals in Cancer Treatment.
    Aschenbrenner DS
    Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749878
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatocellular carcinoma: Current situation and challenge.
    Li Z; Zhu JY
    Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):303-304. PubMed ID: 31253577
    [No Abstract]   [Full Text] [Related]  

  • 16. Regorafenib: a promising treatment for hepatocellular carcinoma.
    Cerrito L; Ponziani FR; Garcovich M; Tortora A; Annicchiarico BE; Pompili M; Siciliano M; Gasbarrini A
    Expert Opin Pharmacother; 2018 Dec; 19(17):1941-1948. PubMed ID: 30345837
    [No Abstract]   [Full Text] [Related]  

  • 17. Regorafenib for the treatment of hepatocellular carcinoma.
    Tovoli F; Granito A; De Lorenzo S; Bolondi L
    Drugs Today (Barc); 2018 Jan; 54(1):5-13. PubMed ID: 29569657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
    Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
    Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune oncology in hepatocellular carcinoma-hype and hope.
    Wörns MA; Galle PR
    Lancet; 2017 Jun; 389(10088):2448-2449. PubMed ID: 28434649
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of regorafenib in hepatocellular carcinoma.
    Frenette CT
    Clin Adv Hematol Oncol; 2017 Feb; 15(2):121-123. PubMed ID: 28398282
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.